Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18-Methoxycoronaridine - Mind Medicine

Drug Profile

18-Methoxycoronaridine - Mind Medicine

Alternative Names: 18-MC

Latest Information Update: 24 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Mindmed; Nonindustrial source
  • Developer Mindmed
  • Class Alkaloids; Carboxylic acids; Drug withdrawal therapies; Esters
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Leishmaniasis; Substance-related disorders

Most Recent Events

  • 24 Sep 2019 18-Methoxycoronaridine is still in phase I trial for Substance-related disorders (In volunteers) in Brazil (PO) (Savant HWP pipeline, September 2019)
  • 24 Sep 2019 18-Methoxycoronaridine is still in phase I trial for Leishmaniasis (In volunteers) in Brazil (PO) (Savant HWP pipeline, September 2019)
  • 16 Sep 2019 Mind Medicine acquires 18-Methoxycoronaridine from Savant HWP
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top